185 related articles for article (PubMed ID: 36709134)
41. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
Fang H; Kapoor P; Gonsalves WI; Frederick LA; Viswanatha D; Howard MT; He R; Morice WG; McPhail ED; Greipp PT; Ansell SM; Kyle RA; Gertz MA; Paludo J; Abeykoon J; King RL
Am J Clin Pathol; 2018 Jul; 150(2):168-176. PubMed ID: 29868855
[TBL] [Abstract][Full Text] [Related]
42. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
[TBL] [Abstract][Full Text] [Related]
43. Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.
Shiseki M; Masuda A; Watanabe N; Fujii M; Kimura T; Yoshinaga K; Mori N; Teramura M; Motoji T
Hematol Rep; 2011 Aug; 3(2):e10. PubMed ID: 22184531
[TBL] [Abstract][Full Text] [Related]
44. Cutaneous Involvement in Waldenström's Macroglobulinaemia.
Stien S; Durot E; Durlach A; Beylot-Barry M; Adamski H; Beltraminelli H; Bohelay G; Carlotti A; Carpentier O; Cornillet P; Dubois R; Franck N; Husson B; Laroche L; Maubec E; le Clech C; Machet L; Ortonne N; Ram-Wolff C; Vergier B; Grange F
Acta Derm Venereol; 2020 Aug; 100(15):adv00225. PubMed ID: 32488284
[TBL] [Abstract][Full Text] [Related]
45. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
[TBL] [Abstract][Full Text] [Related]
46. [Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].
Jia YC; Lu J; Qiang WT; Li L; Liu J; Jiang H; Fu WJ; Du J
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1020-1024. PubMed ID: 33445850
[No Abstract] [Full Text] [Related]
47. B-cell non-Hodgkin lymphoma of the breast in Waldenström's macroglobulinemia: a case report.
Esposito E; Varone V; Siani C; Di Bonito M; Melucci MT; Donzelli I; di Giacomo R; Marone U; Saponara R; Collina F; Fucito A; Avino F
Transl Cancer Res; 2023 Mar; 12(3):651-657. PubMed ID: 37033363
[TBL] [Abstract][Full Text] [Related]
48. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
49. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B
Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852
[TBL] [Abstract][Full Text] [Related]
51. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
[TBL] [Abstract][Full Text] [Related]
52. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
Lin P; Medeiros LJ
Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
[TBL] [Abstract][Full Text] [Related]
53. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
[TBL] [Abstract][Full Text] [Related]
54. Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia.
Kazmierski D; Palomba ML; Barsigian C
Case Rep Hematol; 2017; 2017():5183646. PubMed ID: 28286680
[TBL] [Abstract][Full Text] [Related]
55. Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.
Roberts MJ; Chadburn A; Ma S; Hyjek E; Peterson LC
Am J Clin Pathol; 2013 Feb; 139(2):210-9. PubMed ID: 23355206
[TBL] [Abstract][Full Text] [Related]
56. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
57. Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.
Wang J; Yan Y; Xiong W; Song G; Wang Y; Zhao J; Jia Y; Li C; Yu Z; Yu Y; Chen J; Jiao Y; Wang T; Lyu R; Li Q; Ma Y; Liu W; Zou D; An G; Sun Q; Wang H; Xiao Z; Wang J; Qiu L; Yi S
Blood Adv; 2022 Jul; 6(13):4049-4059. PubMed ID: 35537114
[TBL] [Abstract][Full Text] [Related]
58. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P
Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
[TBL] [Abstract][Full Text] [Related]
59. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
[TBL] [Abstract][Full Text] [Related]
60. VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Mizuta S; Yamane N; Mononobe S; Watanabe A; Matsuki S; Komai T; Koba Y; Mitani S; Kawata T; Tamekane A; Watanabe M
Cytometry B Clin Cytom; 2022 Jan; 102(1):50-61. PubMed ID: 33682304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
